Combination of the PPARα agonist fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone [5]. Here, PPARA is linked to myocardial infarction.